In contrast, tau pathology may be a “downstream” factor in this cascade and has previously been found to be less prevalent than amyloid pathology in DLB, but more closely related to clinical presentation.35 Early data from tau imaging studies have reported conflicting findings on the relationships between amyloid deposition, tau deposition, and clinical profile in DLB.36, 37 Other important pathophysiological factors such as the extent and severity of Lewy body pathology remain unquantifiable until postmortem. The gene discussed is MAPT; the disease is Lewy body dementia.